Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....